Skip to main content
Premium Trial:

Request an Annual Quote

Atreca Licenses Immune Repertoire Capture Technology from Stanford

NEW YORK (GenomeWeb News) – Atreca today announced it has licensed immune repertoire capture technology from Stanford University, which the biopharmaceutical company will develop for a broad range of applications.

The technology was developed in the laboratories of William Robinson, an associate professor of medicine in the Division of Immunology and Rheumatology at Stanford, and leverages next-generation sequencing to identify new antibodies that have utility themselves and that define targets of functional immune response.

"The technology is, therefore, a highly prolific engine for the discovery and development of therapeutic antibodies, vaccines, diagnostics, and research reagents," Robinson said in a statement.

Financial and other terms of the deal were not disclosed.

Atreca, based in San Carlos, Calif., was founded in 2010. Initial investors into the firm include Mission Bay Capital.

The co-founders of the company are Lawrence Steinman, the George A. Zimmerman professor of neurology and neurological sciences and pediatrics at Stanford, and Stanford researchers Robert Axtell; Jeremy Sokolove; Yann Chong Tan; and Guy Cavet.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.